Company has Walker, Chandiok & Co.LLP as its auditors As on 30-06-2020, the company has a total of 282,168,156 shares outstanding.

What's your view on Glenmark Pharmaceuticals for the week?Community outlook on Glenmark Pharmaceuticals for the week.Copyright © 2020 Bennett, Coleman & Co. Ltd. All rights reserved. View live GLENMARK PHARM chart to track its stock's price action. GLENMARK - Q1 results time. Find market predictions, GLENMARK financials and market news. YES Bank 15.50 0.7. ], metabolic disorders [diabetes, obesity, etc.] //./ActionParams/@language -> ... Do like, comment and share. As on 10th Aug 2020 GLENMARK Share Price closed @ 471.30 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 341.55 & Buy for SHORT-TERM with Stoploss of 420.80 we also expect STOCK to react on Following IMPORTANT LEVELS. Nifty 11,322.50 52.35. Cr)

View live GLENMARK PHARM chart to track its stock's price action. (Rs. TradingView India. Glenmark Pharmaceuticals Ltd. key Products/Revenue Segments include Pharmaceuticals which contributed Rs 6072.35 Crore to Sales Value (96.31 % of Total Sales), Other Operating Revenue which contributed Rs 173.73 Crore to Sales Value (2.75 % of Total Sales) and Sale of services which contributed Rs 58.79 Crore to Sales Value (0.93 % of Total Sales)for the year ending 31-Mar-2019.For the quarter ended 31-03-2020, the company has reported a Consolidated sales of Rs 2767.49 Crore, up 1.17 % from last quarter Sales of Rs 2735.56 Crore and up 9.56 % from last year same quarter Sales of Rs 2526.08 Crore Company has reported net profit after tax of Rs 220.31 Crore in latest quarter.The company’s top management includes Dr.Brian W Tempest, Mrs.Cherylann Pinto, Mrs.B E Saldanha, Mr.V S Mani, Mr.Sridhar Gorthi, Mr.Rajesh V Desai, Mr.Milind Sarwate, Mr.Julio Ribeiro, Mr.Glenn Saldanha, Mr.D R Mehta, Mr.Bernard Munos, Ms.Saira Ramasastry. Total Expenditure Around 111,943 shares changed hands on the counter. NSE Gainer-Large Cap . Tax Sales

$page_language -> exchange = NSE, $nseExchange = NSE, $bseExchange = BSE, symbol = GLENMARKEQGlenmark Pharmaceuticals Ltd.Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseGlenmark Pharmaceuticals Ltd.Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationGlenmark Pharmaceuticals Ltd.Closure of Trading WindowGlenmark Pharmaceuticals Ltd.Board Meeting Intimation for Unaudited Financial Results Of The Company For The First Quarter Ended June 30, 2020Glenmark Pharmaceuticals Ltd.Announcement under Regulation 30 (LODR)-Credit RatingGlenmark Pharmaceuticals Ltd.Disclosure Of Related Party Transactions Under Regulation 23(9) Of The SEBI (Listing Obligations And Disclosure Requirem...Glenmark Pharmaceuticals Ltd.Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseGlenmark Pharmaceuticals Ltd.Shareholding for the Period Ended June 30, 2020Glenmark Pharmaceuticals Ltd.Clarification sought from Glenmark Pharmaceuticals LtdGlenmark Pharmaceuticals Ltd.Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseGlenmark Pharmaceuticals Ltd.Compliances-Reg.24(A)-Annual Secretarial ComplianceGlenmark Pharmaceuticals Ltd.Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseGlenmark Pharmaceuticals Ltd.Announcement under Regulation 30 (LODR)-Credit RatingGlenmark Pharmaceuticals Ltd.Board recommends DividendGlenmark Pharmaceuticals Ltd.Audited Financial Results For The Year Ended March 31, 2020Glenmark Pharmaceuticals Ltd.Glenmark Unlocks The Treatment For Mild To Moderate Covid-19 In IndiaGlenmark Pharmaceuticals Ltd.Glenmark Becomes The First Pharmaceutical Company In India To Receive Regulatory Approval For Oral Antiviral Favipiravir...Glenmark Pharmaceuticals Ltd.Indian Regulator Approves Favipiravir For The Treatment Of Mild To Moderate COVID-19 In IndiaGlenmark Pharmaceuticals Ltd.Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseGlenmark Pharmaceuticals Ltd. share price